New pill hopes to shrink lung tumors in early trial
NCT ID NCT06955988
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This early-stage study tests a new tablet, AST2303, in 120 people with advanced non-small cell lung cancer that has spread. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors or slow the disease. Participants will take the tablet and be closely monitored for side effects and cancer response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pfizer drug takes on Hard-to-Treat cancers
- New targeted therapy aims to outshine standard chemo for HER2-mutant lung cancer
- New drug cocktail aims to shrink lung tumors
- New drug cocktail hopes to tackle tough lung cancer
- New combo therapy aims to tackle tough lung cancer
- New pill HRS-4508 targets tough lung cancers